The cannabinoid wellness market has expanded well beyond CBD. CBG, CBN, and CBC are now widely available — but most consumers have little guidance on how these cannabinoids differ, what the science supports, and which formulation is most appropriate for their specific wellness goals. This guide provides a science-based comparison of all four major non-intoxicating cannabinoids in cbdDR's product line.
The Foundation: How Cannabinoids Work
All four cannabinoids interact with the endocannabinoid system (ECS) — a regulatory network of receptors, endogenous ligands, and enzymes that modulates pain, inflammation, mood, sleep, appetite, and immune function. The two primary receptors are CB1 (expressed predominantly in the central nervous system) and CB2 (expressed predominantly in immune tissue and peripheral nervous system). Each cannabinoid has a distinct receptor profile that determines its effects.
CBD — The Foundation Cannabinoid
Primary mechanisms: TRPV1 channel agonism, GPR55 antagonism, adenosine reuptake inhibition, 5-HT1A partial agonism, FAAH inhibition. CBD has low affinity for CB1 and CB2 receptors and works primarily through indirect mechanisms.
Research profile: The most extensively researched cannabinoid. FDA-approved as Epidiolex for two rare epilepsy syndromes. Significant preclinical and clinical research on anxiety, inflammation, pain, and neuroprotection.
Best for: General cannabinoid wellness foundation. Broad-spectrum anxiety and stress support. Starting point for cannabinoid-naive users.
cbdDR formulations: 1000mg CBD-Rich Tincture | 2500mg CBD-Rich Tincture
CBG — The Anti-Inflammatory & Energy Cannabinoid
Primary mechanisms: CB1 and CB2 partial agonism (direct receptor engagement, unlike CBD), alpha-2 adrenoceptor agonism, 5-HT1A antagonism, TRPM8 channel blockade.
Research profile: Preclinical evidence for anti-inflammatory activity via NF-κB pathway inhibition (Borrelli et al., 2013), neuroprotective effects in Huntington's disease model (Valdeolivas et al., 2015), antibacterial activity against MRSA (Farha et al., 2020).
Best for: Anti-inflammatory support. Energy and focus. Users who have plateaued on CBD alone. Daytime use.
cbdDR formulation: 800mg CBG-Rich Tincture — 650mg CBG + 50mg each CBD, CBC, CBN
CBN — The Sleep Cannabinoid
Primary mechanisms: CB1 receptor partial agonism (the most direct CB1 engagement of the four cannabinoids here), CB2 partial agonism, TRPV2 channel activation.
Research profile: CB1 partial agonism provides a plausible pharmacological mechanism for sedative effects. Preclinical sleep-promoting effects in animal models. Human clinical evidence is limited — promising but preliminary.
Best for: Sleep onset and quality support. Evening and nighttime use. Users whose sleep disruption is related to stress, anxiety, or pain.
cbdDR formulation: 800mg CBN-Rich Tincture — 650mg CBN + 50mg each CBD, CBC, CBG
CBC — The Mood & Stress Cannabinoid
Primary mechanisms: TRPV1 and TRPA1 receptor agonism, anandamide reuptake inhibition, TRP channel modulation. CBC has low CB1 and CB2 receptor affinity, similar to CBD.
Research profile: Significant antidepressant-like activity in preclinical models (El-Alfy et al., 2010). Anti-inflammatory activity. Neurogenesis support in preclinical research (Shinjyo & Di Marzo, 2013). Human clinical evidence is limited.
Best for: Anxiety and stress support. Mood support. Daytime use.
cbdDR formulation: 800mg CBC-Rich Tincture — 650mg CBC + 50mg each CBD, CBG, CBN
Quick Reference
- New to cannabinoids / general wellness: 1000mg CBD-Rich Tincture
- Higher concentration needed: 2500mg CBD-Rich Tincture
- Inflammation, joint support, daytime energy: 800mg CBG-Rich Tincture
- Sleep support, nighttime use: 800mg CBN-Rich Tincture
- Anxiety, stress, mood support: 800mg CBC-Rich Tincture
- Targeted topical relief: 2500mg Original Balm or 2500mg Eucalyptus Balm
The Broad Spectrum Advantage
All cbdDR formulations are broad spectrum — each product contains multiple cannabinoids working together through the entourage effect, even when one cannabinoid is dominant. This multi-cannabinoid approach leverages documented synergy while targeting specific wellness outcomes through the dominant cannabinoid's distinct receptor profile.
Shop All cbdDR Formulations → | Verify Any Product's COA → | Why cbdDR →
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare provider before use.